Risperidone versus typical antipsychotic medication for schizophrenia (Q24248755)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

Risperidone versus typical antipsychotic medication for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

0 references

1 reference

1

E Kennedy

E

Kennedy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

F Song

2

F

Song

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

R Hunter

series ordinal

3

author given names

R

author last names

Hunter

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

A Clarke

series ordinal

4

author given names

A

author last names

Clarke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

S Gilbody

series ordinal

5

author given names

S

author last names

Gilbody

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

CD000440

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

Risperidone in the treatment of schizophrenia

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Risperidone versus haloperidol on secondary memory: can newer medications aid learning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Risperidone for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Treatment of the neuroleptic-nonresponsive schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Meta-analysis and the meta-epidemiology of clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Chlorpromazine versus placebo for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

The unit of analysis error in studies about physicians' patient care behavior

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Why register clinical trials?--Revisited

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Five factor model of schizophrenia: replication across samples

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Treatment-resistant schizophrenia: clinical experience with new antipsychotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Pardonable revisions and protocol reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD000440

1 reference

7 January 2021

Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD000440

1 reference

7 January 2021

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Effect of risperidone on hostility in schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

A risk-benefit assessment of risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Antipsychotic drugs: clinical pharmacology and therapeutic use.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone: review of its pharmacology and therapeutic use in schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000440

7 January 2021

10.1002/14651858.CD000440

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10796543%20AND%20SRC:MED&resulttype=core&format=json

release_tnkoteqgpbc7xogt32opymdvjq

6 November 2019

Fatcat ID

0 references

0 references

1 reference